Targeted Approaches Applied to Uncommon Diseases: A Case of Salivary Duct Carcinoma Metastatic to the Brain Treated with the Multikinase Inhibitor Neratinib

Karl R. Sorenson, Guilherme Piovezani Ramos, Jose (J.C.) Villasboas Bisneto, Katharine Price

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Salivary duct carcinoma is a rare malignancy associated with hormone receptor and human epidermal growth factor receptor 2 (HER2) overexpression. Local surgical control is the cornerstone of therapy, but a subset of patients develops metastatic disease portending a poor prognosis and limited management options. Intracranial metastases are an uncommon manifestation and present a therapeutic challenge. We report the case of a 31-year-old male who presented with facial pain and swelling subsequently diagnosed with salivary duct carcinoma. Our patient underwent extensive locoregional resection and analysis of the tumor tissue demonstrated evidence of androgen receptor expression and HER2 overexpression. His course was complicated by metastatic extra-and intracranial recurrence despite combined modality treatment with radiation and chemotherapy followed by anti-HER2 monoclonal antibody therapy and androgen deprivation therapy. After exhausting standard treatment options, he received experimental therapy with a new small-molecule tyrosine kinase inhibitor, neratinib, with evidence of a transient clinical response and no significant adverse effects. This case exemplifies the potential and limitations of targeted therapy, particularly when applied to patients with rare diseases and presentations.

Original languageEnglish (US)
Pages (from-to)726-731
Number of pages6
JournalCase Reports in Oncology
Volume10
Issue number2
DOIs
StatePublished - May 5 2017

Fingerprint

Salivary Ducts
Carcinoma
Brain
Therapeutics
Facial Pain
Investigational Therapies
Androgen Receptors
Rare Diseases
N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide
Protein-Tyrosine Kinases
Androgens
Neoplasms
Monoclonal Antibodies
Hormones
Radiation
Neoplasm Metastasis
Recurrence
Drug Therapy

Keywords

  • Human epidermal growth factor receptor 2
  • Intracranial metastasis
  • Neratinib
  • Salivary duct carcinoma
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Targeted Approaches Applied to Uncommon Diseases : A Case of Salivary Duct Carcinoma Metastatic to the Brain Treated with the Multikinase Inhibitor Neratinib. / Sorenson, Karl R.; Piovezani Ramos, Guilherme; Villasboas Bisneto, Jose (J.C.); Price, Katharine.

In: Case Reports in Oncology, Vol. 10, No. 2, 05.05.2017, p. 726-731.

Research output: Contribution to journalArticle

@article{8cae19c1f0f049868fae5b41a840f2c2,
title = "Targeted Approaches Applied to Uncommon Diseases: A Case of Salivary Duct Carcinoma Metastatic to the Brain Treated with the Multikinase Inhibitor Neratinib",
abstract = "Salivary duct carcinoma is a rare malignancy associated with hormone receptor and human epidermal growth factor receptor 2 (HER2) overexpression. Local surgical control is the cornerstone of therapy, but a subset of patients develops metastatic disease portending a poor prognosis and limited management options. Intracranial metastases are an uncommon manifestation and present a therapeutic challenge. We report the case of a 31-year-old male who presented with facial pain and swelling subsequently diagnosed with salivary duct carcinoma. Our patient underwent extensive locoregional resection and analysis of the tumor tissue demonstrated evidence of androgen receptor expression and HER2 overexpression. His course was complicated by metastatic extra-and intracranial recurrence despite combined modality treatment with radiation and chemotherapy followed by anti-HER2 monoclonal antibody therapy and androgen deprivation therapy. After exhausting standard treatment options, he received experimental therapy with a new small-molecule tyrosine kinase inhibitor, neratinib, with evidence of a transient clinical response and no significant adverse effects. This case exemplifies the potential and limitations of targeted therapy, particularly when applied to patients with rare diseases and presentations.",
keywords = "Human epidermal growth factor receptor 2, Intracranial metastasis, Neratinib, Salivary duct carcinoma, Targeted therapy",
author = "Sorenson, {Karl R.} and {Piovezani Ramos}, Guilherme and {Villasboas Bisneto}, {Jose (J.C.)} and Katharine Price",
year = "2017",
month = "5",
day = "5",
doi = "10.1159/000479499",
language = "English (US)",
volume = "10",
pages = "726--731",
journal = "Case Reports in Oncology",
issn = "1662-6575",
number = "2",

}

TY - JOUR

T1 - Targeted Approaches Applied to Uncommon Diseases

T2 - A Case of Salivary Duct Carcinoma Metastatic to the Brain Treated with the Multikinase Inhibitor Neratinib

AU - Sorenson, Karl R.

AU - Piovezani Ramos, Guilherme

AU - Villasboas Bisneto, Jose (J.C.)

AU - Price, Katharine

PY - 2017/5/5

Y1 - 2017/5/5

N2 - Salivary duct carcinoma is a rare malignancy associated with hormone receptor and human epidermal growth factor receptor 2 (HER2) overexpression. Local surgical control is the cornerstone of therapy, but a subset of patients develops metastatic disease portending a poor prognosis and limited management options. Intracranial metastases are an uncommon manifestation and present a therapeutic challenge. We report the case of a 31-year-old male who presented with facial pain and swelling subsequently diagnosed with salivary duct carcinoma. Our patient underwent extensive locoregional resection and analysis of the tumor tissue demonstrated evidence of androgen receptor expression and HER2 overexpression. His course was complicated by metastatic extra-and intracranial recurrence despite combined modality treatment with radiation and chemotherapy followed by anti-HER2 monoclonal antibody therapy and androgen deprivation therapy. After exhausting standard treatment options, he received experimental therapy with a new small-molecule tyrosine kinase inhibitor, neratinib, with evidence of a transient clinical response and no significant adverse effects. This case exemplifies the potential and limitations of targeted therapy, particularly when applied to patients with rare diseases and presentations.

AB - Salivary duct carcinoma is a rare malignancy associated with hormone receptor and human epidermal growth factor receptor 2 (HER2) overexpression. Local surgical control is the cornerstone of therapy, but a subset of patients develops metastatic disease portending a poor prognosis and limited management options. Intracranial metastases are an uncommon manifestation and present a therapeutic challenge. We report the case of a 31-year-old male who presented with facial pain and swelling subsequently diagnosed with salivary duct carcinoma. Our patient underwent extensive locoregional resection and analysis of the tumor tissue demonstrated evidence of androgen receptor expression and HER2 overexpression. His course was complicated by metastatic extra-and intracranial recurrence despite combined modality treatment with radiation and chemotherapy followed by anti-HER2 monoclonal antibody therapy and androgen deprivation therapy. After exhausting standard treatment options, he received experimental therapy with a new small-molecule tyrosine kinase inhibitor, neratinib, with evidence of a transient clinical response and no significant adverse effects. This case exemplifies the potential and limitations of targeted therapy, particularly when applied to patients with rare diseases and presentations.

KW - Human epidermal growth factor receptor 2

KW - Intracranial metastasis

KW - Neratinib

KW - Salivary duct carcinoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85027154419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027154419&partnerID=8YFLogxK

U2 - 10.1159/000479499

DO - 10.1159/000479499

M3 - Article

AN - SCOPUS:85027154419

VL - 10

SP - 726

EP - 731

JO - Case Reports in Oncology

JF - Case Reports in Oncology

SN - 1662-6575

IS - 2

ER -